| Primary |
| Cardiac Failure |
13.8% |
| Product Used For Unknown Indication |
13.8% |
| Angina Pectoris |
6.9% |
| Hypertension |
6.9% |
| Hyperuricaemia |
6.9% |
| Laceration |
6.9% |
| Myocardial Infarction |
6.9% |
| Abdominal Pain Upper |
3.4% |
| Blood Uric Acid Increased |
3.4% |
| Bronchitis Chronic |
3.4% |
| Depression |
3.4% |
| Gastritis |
3.4% |
| Hypercholesterolaemia |
3.4% |
| Hyperlipidaemia |
3.4% |
| Neuralgia |
3.4% |
| Osteoporosis |
3.4% |
| Spinal Osteoarthritis |
3.4% |
| Vertigo |
3.4% |
|
| Toxic Skin Eruption |
40.0% |
| Drug Eruption |
20.0% |
| Toxic Epidermal Necrolysis |
20.0% |
| Ulcer |
20.0% |
|
| Secondary |
| Product Used For Unknown Indication |
26.1% |
| Drug Use For Unknown Indication |
15.0% |
| Hypertension |
9.1% |
| Prophylaxis |
8.1% |
| Chronic Hepatitis C |
7.5% |
| Hyperuricaemia |
7.1% |
| Adult T-cell Lymphoma/leukaemia |
4.2% |
| Multiple Myeloma |
3.6% |
| Benign Prostatic Hyperplasia |
3.0% |
| Gout |
2.6% |
| Urinary Tract Infection |
2.1% |
| Lymphoma |
1.8% |
| Adverse Event |
1.4% |
| Cardiomyopathy |
1.3% |
| Chronic Lymphocytic Leukaemia |
1.3% |
| Constipation |
1.2% |
| Hepatitis C |
1.2% |
| Cardiac Failure |
1.1% |
| Prophylaxis Urinary Tract Infection |
1.1% |
| Type 2 Diabetes Mellitus |
1.1% |
|
| Varicella |
11.4% |
| Stevens-johnson Syndrome |
8.9% |
| Toxic Epidermal Necrolysis |
7.5% |
| Toxic Skin Eruption |
7.5% |
| Rash |
6.0% |
| Renal Failure Acute |
6.0% |
| Urticaria |
5.7% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
5.3% |
| Interstitial Lung Disease |
5.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.6% |
| Renal Impairment |
4.3% |
| Rhabdomyolysis |
4.3% |
| White Blood Cell Count Decreased |
4.3% |
| Neuropathy Peripheral |
3.2% |
| Transaminases Increased |
3.2% |
| Hypertriglyceridaemia |
2.8% |
| Jaundice |
2.5% |
| Liver Disorder |
2.5% |
| Skin Lesion |
2.5% |
| Staphylococcal Sepsis |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
19.3% |
| Hypertension |
13.5% |
| Prophylaxis |
13.1% |
| Drug Use For Unknown Indication |
13.0% |
| Chronic Hepatitis C |
7.8% |
| Hyperuricaemia |
5.7% |
| Hepatitis C |
3.0% |
| Diabetes Mellitus |
2.7% |
| Multiple Myeloma |
2.6% |
| Rheumatoid Arthritis |
2.4% |
| Chronic Myeloid Leukaemia |
2.3% |
| Cardiac Failure |
2.1% |
| Constipation |
2.0% |
| Insomnia |
1.8% |
| Atrial Fibrillation |
1.6% |
| Type 2 Diabetes Mellitus |
1.6% |
| Gastritis |
1.5% |
| Hyperlipidaemia |
1.4% |
| Infection Prophylaxis |
1.3% |
| Psoriasis |
1.3% |
|
| White Blood Cell Count Decreased |
14.2% |
| Renal Failure Acute |
9.0% |
| Renal Impairment |
8.6% |
| Vomiting |
7.9% |
| Rash |
7.2% |
| Thrombocytopenia |
5.9% |
| Pyrexia |
5.1% |
| Renal Failure |
4.9% |
| Platelet Count Decreased |
4.8% |
| Rhabdomyolysis |
3.9% |
| Stomatitis |
3.3% |
| Anaemia |
3.2% |
| White Blood Cell Count Increased |
3.0% |
| Pneumonia |
2.9% |
| Myocardial Infarction |
2.8% |
| Syncope |
2.8% |
| Sepsis |
2.7% |
| Interstitial Lung Disease |
2.5% |
| Liver Disorder |
2.5% |
| Malaise |
2.5% |
|
| Interacting |
| Drug Use For Unknown Indication |
22.4% |
| Prophylaxis |
16.3% |
| Multiple Myeloma |
8.2% |
| Product Used For Unknown Indication |
8.2% |
| Prophylaxis Against Transplant Rejection |
6.1% |
| Cardiomyopathy |
4.1% |
| Gout |
4.1% |
| Hypercholesterolaemia |
4.1% |
| Ventricular Dysfunction |
4.1% |
| Allergic Granulomatous Angiitis |
2.0% |
| Asthma |
2.0% |
| Atrial Fibrillation |
2.0% |
| Gastrooesophageal Reflux Disease |
2.0% |
| Hairy Cell Leukaemia |
2.0% |
| Hypertension |
2.0% |
| Hyperuricaemia |
2.0% |
| Neuralgia |
2.0% |
| Prostatomegaly |
2.0% |
| Pulmonary Arterial Hypertension |
2.0% |
| Ventricular Tachycardia |
2.0% |
|
| Erythema Multiforme |
11.1% |
| International Normalised Ratio Increased |
11.1% |
| Meningitis Cryptococcal |
11.1% |
| Multiple Myeloma |
11.1% |
| Rash Generalised |
11.1% |
| Rectal Haemorrhage |
11.1% |
| Renal Failure Acute |
11.1% |
| Varices Oesophageal |
11.1% |
| Ventricular Tachycardia |
11.1% |
|
